Shattuck Labs (STTK) to Release Quarterly Earnings on Thursday

Shattuck Labs (NASDAQ:STTK) is expected to be posting its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Shattuck Labs to post earnings of ($0.12) per share and revenue of $0.1670 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 6:30 AM ET.

Shattuck Labs (NASDAQ:STTK) last released its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). The company had revenue of ($1.00) million during the quarter, compared to the consensus estimate of $0.17 million. On average, analysts expect Shattuck Labs to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shattuck Labs Price Performance

STTK opened at $6.12 on Wednesday. The stock’s 50 day simple moving average is $4.64 and its 200 day simple moving average is $3.27. Shattuck Labs has a 1 year low of $0.69 and a 1 year high of $6.31. The firm has a market cap of $437.95 million, a price-to-earnings ratio of -7.95 and a beta of 1.55.

Analyst Ratings Changes

A number of analysts have recently weighed in on STTK shares. Needham & Company LLC started coverage on Shattuck Labs in a research note on Friday, March 6th. They set a “buy” rating and a $25.00 price objective for the company. TD Cowen reaffirmed a “buy” rating on shares of Shattuck Labs in a research note on Friday, March 6th. HC Wainwright upgraded shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price target for the company in a report on Monday, December 1st. Piper Sandler started coverage on shares of Shattuck Labs in a research report on Wednesday, January 28th. They set an “overweight” rating and a $15.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Shattuck Labs in a report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Shattuck Labs currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.50.

Hedge Funds Weigh In On Shattuck Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in Shattuck Labs in the third quarter worth $38,000. Squarepoint Ops LLC bought a new stake in Shattuck Labs in the third quarter valued at $46,000. Dimensional Fund Advisors LP purchased a new position in Shattuck Labs during the 4th quarter valued at $85,000. OMERS ADMINISTRATION Corp bought a new position in Shattuck Labs in the 4th quarter worth $97,000. Finally, Invesco Ltd. bought a new position in Shattuck Labs in the 4th quarter worth $103,000. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.